The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The in vivo efficacy of docetaxel and cabazitaxel in a cell-line based xenograft of castration-resistant prostate cancer (CRPC) previously treated with enzalutamide.
Robert J. van Soest
No relevant relationships to disclose
Ellen S. de Morrée
No relevant relationships to disclose
Corrina M.A. de Ridder
No relevant relationships to disclose
Herman Burger
No relevant relationships to disclose
Erik A.C. Wiemer
No relevant relationships to disclose
Ron H.J. Mathijssen
No relevant relationships to disclose
Wytske M. van Weerden
No relevant relationships to disclose
Ronald De Wit
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi